ZA953879B - Protein production and protein delivery - Google Patents

Protein production and protein delivery

Info

Publication number
ZA953879B
ZA953879B ZA953879A ZA953879A ZA953879B ZA 953879 B ZA953879 B ZA 953879B ZA 953879 A ZA953879 A ZA 953879A ZA 953879 A ZA953879 A ZA 953879A ZA 953879 B ZA953879 B ZA 953879B
Authority
ZA
South Africa
Prior art keywords
protein
delivery
production
protein production
protein delivery
Prior art date
Application number
ZA953879A
Other languages
English (en)
Inventor
Douglas A Treco
Michael W Heartlein
Richard F Selden
Original Assignee
Transkaryotic Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22918596&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA953879(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Transkaryotic Therapies Inc filed Critical Transkaryotic Therapies Inc
Publication of ZA953879B publication Critical patent/ZA953879B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/55—Vector systems having a special element relevant for transcription from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/70—Vector systems having a special element relevant for transcription from fungi
    • C12N2830/702—Vector systems having a special element relevant for transcription from fungi yeast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA953879A 1994-05-13 1995-05-12 Protein production and protein delivery ZA953879B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/243,391 US5641670A (en) 1991-11-05 1994-05-13 Protein production and protein delivery

Publications (1)

Publication Number Publication Date
ZA953879B true ZA953879B (en) 1996-01-18

Family

ID=22918596

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA953879A ZA953879B (en) 1994-05-13 1995-05-12 Protein production and protein delivery

Country Status (19)

Country Link
US (1) US5641670A (hu)
EP (1) EP0759082A1 (hu)
JP (1) JPH10500570A (hu)
KR (1) KR100379356B1 (hu)
AU (1) AU709058B2 (hu)
BR (1) BR9507874A (hu)
CA (1) CA2190289A1 (hu)
CZ (1) CZ295115B6 (hu)
FI (1) FI964536A (hu)
HU (1) HUT76844A (hu)
IL (1) IL113708A0 (hu)
MX (1) MX9605542A (hu)
NO (1) NO964802L (hu)
NZ (1) NZ285945A (hu)
RU (1) RU2267533C2 (hu)
SK (1) SK146196A3 (hu)
UA (1) UA34493C2 (hu)
WO (1) WO1995031560A1 (hu)
ZA (1) ZA953879B (hu)

Families Citing this family (330)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
GEP20033145B (en) * 1989-10-16 2003-12-25 Amgen Inc Stem Cell Factor
US6852313B1 (en) 1989-10-16 2005-02-08 Amgen Inc. Method of stimulating growth of melanocyte cells by administering stem cell factor
US20040181044A1 (en) * 1989-10-16 2004-09-16 Zsebo Krisztina M. Method of stimulating growth of epithelial cells by administering stem cell factor
US7144731B2 (en) * 1989-10-16 2006-12-05 Amgen Inc. SCF antibody compositions and methods of using the same
US5733761A (en) * 1991-11-05 1998-03-31 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6270989B1 (en) * 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
US5981730A (en) 1994-04-13 1999-11-09 The General Hospital Corporation RPS gene family, primers, probes, and detection methods
US7820798B2 (en) * 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7597886B2 (en) * 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
WO1998007860A1 (en) * 1996-08-23 1998-02-26 Chiron Corporation HUMAN POLYHOMEOTIC 1 (hph1) ACTS AS AN ONCOGENE
AU4424597A (en) * 1996-09-13 1998-04-02 Novo Nordisk Biotech, Inc. Cells having dna insertion mutations which produce altered amounts of a polypeptide
AU4424497A (en) 1996-09-13 1998-04-02 Transkaryotic Therapies, Inc. Therapy for alpha-galactosidase a deficiency
EP0954585B1 (en) 1996-10-01 2009-11-25 Geron Corporation Human telomerase reverse transcriptase promoter
US6136566A (en) * 1996-10-04 2000-10-24 Lexicon Graphics Incorporated Indexed library of cells containing genomic modifications and methods of making and utilizing the same
US6855545B1 (en) 1996-10-04 2005-02-15 Lexicon Genetics Inc. Indexed library of cells containing genomic modifications and methods of making and utilizing the same
US7332338B2 (en) 1996-10-04 2008-02-19 Lexicon Pharmaceuticals, Inc. Vectors for making genomic modifications
US20040072243A1 (en) * 1996-10-11 2004-04-15 Lexicon Genetics Incorporated Indexed library of cells containing genomic modifications and methods of making and utilizing the same
WO1998024477A1 (en) 1996-12-06 1998-06-11 Amgen Inc. Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
EP0948531A1 (en) * 1996-12-11 1999-10-13 Chiron Corporation Secreted human proteins
US20020168718A1 (en) * 1997-04-03 2002-11-14 California Institute Of Technology Enzyme-mediated modification of fibrin for tissue engineering
ATE414775T1 (de) 1997-05-16 2008-12-15 Novozymes Inc Polypeptide mit prolyldipeptidylaminopeptidase- aktivität und dafür kodierende nukleinsäuren
US6639050B1 (en) 1997-07-21 2003-10-28 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US7378506B2 (en) * 1997-07-21 2008-05-27 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
ES2281133T3 (es) * 1997-07-23 2007-09-16 Roche Diagnostics Gmbh Identificacion de lineas celulares humanas para la produccion de proteinas humanas mediante la activacion endogena de genes.
AU776280B2 (en) * 1997-07-23 2004-09-02 Roche Diagnostics Gmbh Production of erythropoietin by endogenous gene activation
US6548296B1 (en) 1997-07-23 2003-04-15 Roche Diagnostics Gmbh Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof
PT1000154E (pt) * 1997-07-23 2007-03-30 Roche Diagnostics Gmbh Identificação de linhas celulares humanas para a produção de proteínas humanas por activação endógena de genes
EP1000167B2 (de) 1997-07-23 2011-04-20 Roche Diagnostics GmbH Herstellung humaner mutierter proteine in humanen zellen mittels homologer rekombination
US6391633B1 (en) 1997-07-23 2002-05-21 Roche Diagnostics Gmbh Production of erythropoietin by endogenous gene activation
EP0986644B1 (de) * 1997-07-23 2006-10-04 Boehringer Mannheim GmbH Herstellung von erythropoietin durch endogene genaktivierung mit viralen promotoren
NZ504185A (en) * 1997-09-26 2003-02-28 Athersys Inc Expression of endogenous genes by non-homologous recombination of a vector construct with cellular DNA
US6740503B1 (en) 1997-09-26 2004-05-25 Athersys, Inc. Compositions and methods for non-targeted activation of endogenous genes
US6897066B1 (en) * 1997-09-26 2005-05-24 Athersys, Inc. Compositions and methods for non-targeted activation of endogenous genes
ZA989497B (en) * 1997-10-20 2000-04-19 Roche Diagnostics Gmbh Positive-negative selection in homologous recombination.
JP4441112B2 (ja) 1997-11-03 2010-03-31 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 新脈管形成および腫瘍増殖のインヒビターであるｖｅｇｉ
AR022358A1 (es) * 1997-12-03 2002-09-04 Roche Olivier Una composicion de epo, un procedimiento para su obtencion, un preparado farmaceutico que la contiene y un procedimiento para aumentar la actividadespecifica de una composicion de epo
ATE284443T1 (de) 1998-02-19 2004-12-15 Eastern Virginia Med School Rekombinantes aktives humänes zona pellucida protein 3 (hzp3)
US7037663B2 (en) * 1998-02-19 2006-05-02 Eastern Virginia Medical School Human zona pellucida protein 3 and uses thereof
AU3066699A (en) 1998-03-03 1999-09-20 Johns Hopkins University, The Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation
ATE490980T1 (de) 1998-03-19 2010-12-15 Human Genome Sciences Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor
US6436707B1 (en) * 1998-03-27 2002-08-20 Lexicon Genetics Incorporated Vectors for gene mutagenesis and gene discovery
US6808921B1 (en) * 1998-03-27 2004-10-26 Lexicon Genetics Incorporated Vectors for gene mutagenesis and gene discovery
JP2002513566A (ja) 1998-05-07 2002-05-14 トランスカリョティック セラピーズ インコーポレーテッド 相同組換えによるＦＳＨβ遺伝子の発現の改変
KR20010071207A (ko) 1998-05-07 2001-07-28 추후제출 단백질 생산 및 전달을 위한 인간 과립구 콜로니-자극인자 유전자의 코딩 영역 상류의 지놈 서열
KR20010052278A (ko) * 1998-05-07 2001-06-25 트랜스카리오틱 쎄라피즈, 인코포레이티드 단백질 생산 및 전달을 위한 인터페론-알파 2 유전자 코딩영역 상류의 지놈 서열
AU4213999A (en) * 1998-05-27 1999-12-13 Novo Nordisk Biotech, Inc. Methods for producing a polypeptide by modifying the copy number of a gene
AU771111B2 (en) 1998-07-21 2004-03-11 Emd Millipore Corporation A polynucleotide comprising a ubiquitous chromatin opening element (UCOE)
US6894022B1 (en) 1998-08-27 2005-05-17 Eidgenossische Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering
US7601685B2 (en) * 1998-08-27 2009-10-13 Eidgenossische Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering
US7241730B2 (en) 1998-08-27 2007-07-10 Universitat Zurich Enzyme-mediated modification of fibrin for tissue engineering: fibrin formulations with peptides
SE9803099D0 (sv) 1998-09-13 1998-09-13 Karolinska Innovations Ab Nucleic acid transfer
EP1121437B1 (en) 1998-10-15 2008-02-20 Novartis Vaccines and Diagnostics, Inc. Metastatic breast and colon cancer regulated genes
US6416975B1 (en) 1998-11-12 2002-07-09 Gliatech, Inc. Human glycine transporter type 2
WO2000034474A2 (en) 1998-12-07 2000-06-15 Zymogenetics, Inc. Growth factor homolog zvegf3
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
EP1961813B1 (en) 1998-12-16 2011-08-10 Novartis Vaccines and Diagnostics, Inc. Human cyclin-dependent kinase (hPNQALRE)
AU3003700A (en) * 1999-02-19 2000-09-04 Athersys, Inc. Compositions and methods for non-targeted activation of endogenous genes
WO2000050620A2 (en) 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
AU3731400A (en) 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Methods and compositions useful in inhibiting apoptosis
US6849605B1 (en) * 1999-03-05 2005-02-01 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
WO2000051623A2 (en) 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
WO2000051625A1 (en) * 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses
ATE377076T1 (de) 1999-03-09 2007-11-15 Zymogenetics Inc Humanes cytokin als ligand des zalpha rezeptors und dessen verwendungen
EP1194572A2 (en) 1999-03-22 2002-04-10 Novozymes Biotech, Inc. Promoter sequences derived from fusarium venenatum and uses thereof
US7112341B1 (en) 1999-04-13 2006-09-26 Nektar Therapeutics Pulmonary administration of dry powder formulations for treating infertility
AU6403700A (en) * 1999-06-15 2001-01-02 Genetrol Biotherapeutics, Inc. Methods for enhancing the production of cytokines in cell culture
ES2364086T3 (es) 1999-07-07 2011-08-24 Zymogenetics, Inc. Receptor de citoquina humana.
EP2275559A3 (en) 1999-09-28 2011-03-23 Shire Human Genetic Therapies, Inc. Optimized messenger RNA
EP1305412A2 (en) 1999-10-14 2003-05-02 Clontech Laboratories Inc. Anthozoa derived chromo/fluoroproteins and methods for using the same
WO2001036643A1 (en) * 1999-11-19 2001-05-25 Transkaryotic Therapies, Inc. Nucleic acid construct for optimized production of products
CA2392019A1 (en) 1999-11-22 2001-05-31 Zymogenetics, Inc. Method of forming a peptide-receptor complex with zsig33
US8168178B2 (en) 1999-11-30 2012-05-01 Curis, Inc. Methods and compositions for regulating lymphocyte activity
US6951839B1 (en) 1999-11-30 2005-10-04 Curis, Inc. Methods and compositions for regulating lymphocyte activity
WO2001042442A2 (en) * 1999-12-10 2001-06-14 Cytos Biotechnology Ag Activation of endogenous genes by genomic introduction of a replicon
EP1242600B1 (en) 1999-12-23 2010-03-03 ZymoGenetics, Inc. Cytokine zcyto18
EP1248841B1 (en) 2000-01-10 2008-07-23 Novartis Vaccines and Diagnostics, Inc. Genes differentially expressed in breast cancer
TW201006846A (en) 2000-03-07 2010-02-16 Senomyx Inc T1R taste receptor and genes encidung same
US6569681B1 (en) * 2000-03-14 2003-05-27 Transkaryotic Therapies, Inc. Methods of improving homologous recombination
US20030084471A1 (en) 2000-03-16 2003-05-01 David Beach Methods and compositions for RNA interference
EP1728862A1 (en) 2000-03-16 2006-12-06 Genetica, Inc. Methods and compositions for RNA interference
CA2405557C (en) 2000-04-12 2013-09-24 Human Genome Sciences, Inc. Albumin fusion proteins
US20020077775A1 (en) * 2000-05-25 2002-06-20 Schork Nicholas J. Methods of DNA marker-based genetic analysis using estimated haplotype frequencies and uses thereof
US20030195707A1 (en) * 2000-05-25 2003-10-16 Schork Nicholas J Methods of dna marker-based genetic analysis using estimated haplotype frequencies and uses thereof
WO2001096528A2 (en) 2000-06-15 2001-12-20 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
GB0018876D0 (en) * 2000-08-01 2000-09-20 Applied Research Systems Method of producing polypeptides
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US7138262B1 (en) * 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
EP2157183A1 (en) 2000-08-25 2010-02-24 BASF Plant Science GmbH Plant polynucleotides encoding prenyl proteases
US20020150541A1 (en) * 2000-09-12 2002-10-17 Gene Trol Biotherapeutics, Inc. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
CA2422060A1 (en) * 2000-09-12 2002-03-21 Genetrol Biotherapeutics, Inc. Compositions comprising mixtures of human cytokines and methods of producing the same
US20030129162A1 (en) * 2000-09-12 2003-07-10 Lau Allan S. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
US7381713B2 (en) * 2000-12-04 2008-06-03 Sioan-Kettering Institute For Cancer Research Treatment of cancer by reduction of intracellular energy and pyrimidines
EP1349555A4 (en) * 2000-12-04 2007-04-25 Sloan Kettering Inst Cancer TREATMENT OF CANCER BY REDUCING INTRA-CELLULAR ENERGY AND PYRIMIDINES
ATE505204T1 (de) 2000-12-20 2011-04-15 Hoffmann La Roche Konjugate von erythropoietin (epo) mit polyethylenglykol (peg)
KR100645843B1 (ko) * 2000-12-20 2006-11-14 에프. 호프만-라 로슈 아게 에리트로포이에틴 접합체
TW201022287A (en) 2001-01-03 2010-06-16 Senomyx Inc T1R taste receptors and genes encoding same
WO2002059337A1 (en) * 2001-01-26 2002-08-01 Georgetown University School Of Medicine Anti-apoptopic gene scc-s2 and diagnostic and therapeutic uses thereof
CA2437811A1 (en) 2001-02-09 2002-08-22 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
ATE434936T1 (de) 2001-03-14 2009-07-15 Myriad Genetics Inc Tsg101-gag-wechselwirkung und ihre verwendung
US7883856B2 (en) 2001-04-05 2011-02-08 Senomyx Inc. Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators
US7338771B2 (en) 2001-07-10 2008-03-04 Alexey Pronin Use of specific T2R taste receptors to identify compounds that block bitter taste
AU2002303261A1 (en) * 2001-04-06 2002-10-21 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
AU2002305151A1 (en) * 2001-04-06 2002-10-21 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
WO2002081640A2 (en) * 2001-04-06 2002-10-17 Georgetown University Gene shinc-1 and diagnostic and therapeutic uses thereof
WO2002081642A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
EP1385864B1 (en) 2001-04-13 2010-06-09 Human Genome Sciences, Inc. Anti-VEGF-2 antibodies
US7309783B2 (en) * 2001-05-09 2007-12-18 The University Of Connecticut Mammalian early developmental regulator gene
WO2002091999A2 (en) * 2001-05-09 2002-11-21 Geron Corporation Treatment for wounds
CN100489102C (zh) 2001-06-26 2009-05-20 塞诺米克斯公司 T1r异源寡聚的味觉受体和表达所述受体的细胞系及其在鉴定味觉化合物中的用途
US6867189B2 (en) * 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
US7148021B2 (en) * 2001-08-02 2006-12-12 Eastern Virginia Meical School Human zona pellucida proteins and methods of their use in diagnosing male infertility
JP2005511012A (ja) * 2001-08-10 2005-04-28 セローノ ジェネティクス インスティテュート ソシエテ アノニム ヒトｃＤＮＡおよびタンパク質およびその使用
US20050064587A1 (en) * 2001-09-07 2005-03-24 Lawrence Rosenberg Pancreatic small cells and uses thereof
MXPA04004671A (es) 2001-11-14 2005-08-25 Johnson & Johnson Anticuerpos anti-interleucina-6, composiciones, metodos y usos.
CA2468408A1 (en) * 2001-11-28 2003-06-05 Genset S.A. Human cdnas and proteins and uses thereof
US7247609B2 (en) * 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
ES2329666T3 (es) * 2001-12-19 2009-11-30 The University Of Chicago Proteinas fluorescentes de maduracion rapida y procedimientos de uso de las mismas.
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
ES2545090T3 (es) 2001-12-21 2015-09-08 Human Genome Sciences, Inc. Proteínas de fusión de albúmina y GCSF
RU2360923C2 (ru) 2002-01-18 2009-07-10 Займоджинетикс, Инк. Новый лиганд рецептора цитокина zcytor17
NZ534310A (en) 2002-02-07 2008-03-28 Novozymes Delta Ltd Albumin-fused anti-angiogenesis peptides
CA2476894A1 (en) 2002-02-20 2003-08-28 American Integrated Biologics, Inc. Transgenic production in saliva
EP1485475B2 (en) * 2002-03-15 2017-09-20 Cellectis Hybrid and single chain meganucleases and use thereof
US20100151556A1 (en) * 2002-03-15 2010-06-17 Cellectis Hybrid and single chain meganucleases and use thereof
WO2009095742A1 (en) * 2008-01-31 2009-08-06 Cellectis New i-crei derived single-chain meganuclease and uses thereof
US7138512B2 (en) * 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
US7244565B2 (en) * 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
AU2003231028A1 (en) 2002-04-22 2003-11-03 Novozymes Biotech, Inc. Methods for increasing homologous recombination of a nucleic acid sequence
US20040071686A1 (en) 2002-04-25 2004-04-15 Treco Douglas A. Treatment of alpha-galactosidase A deficiency
US20030228317A1 (en) * 2002-05-22 2003-12-11 Prafulla Gokhale Gene BRCC-1 and diagnostic and therapeutic uses thereof
AU2003254016A1 (en) 2002-07-19 2004-02-09 Catholic Healthcare West Methods and compositions relating to chimeric nicotinic receptor subunits
US7459435B2 (en) * 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
JP4490284B2 (ja) 2002-11-18 2010-06-23 ノボザイムス，インコーポレイティド 菌類細胞において遺伝子を発現するためのプロモーター変異体
US7459436B2 (en) * 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
WO2004048551A2 (en) * 2002-11-22 2004-06-10 The Johns Hopkins University Target for therapy of cognitive impairment
AU2003298816C1 (en) * 2002-12-02 2010-12-16 Amgen Fremont, Inc. Antibodies directed to Tumor Necrosis Factor and uses thereof
JP2006508666A (ja) * 2002-12-10 2006-03-16 オタワ ヘルス リサーチ インスティテュート カスパーゼ３活性調節による幹細胞分化の調節
US20050048041A1 (en) * 2003-01-13 2005-03-03 Rao Mahendra S. Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products
CA2802143C (en) 2003-01-14 2018-06-19 Dana-Farber Cancer Institute Sparc encoding polynucleotide as a cancer therapy sensitizer
MXPA05007615A (es) * 2003-01-21 2005-09-30 Bristol Myers Squibb Co Polinucleotido que codifica una novedosa acil coenzima a, monoacilglicerol aciltransferasa-3 (mgat3), y usos del mismo.
AU2004208031B2 (en) 2003-01-28 2009-10-08 Cellectis Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof.
CA2515708A1 (en) 2003-02-11 2004-08-26 Transkaryotic Therapies, Inc. Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies
WO2004098634A2 (en) * 2003-04-30 2004-11-18 Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health Protein arginine n-methyltransferase 2 (prmt-2)
US20060252120A1 (en) * 2003-05-09 2006-11-09 Kieliszewski Marcia J Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
AU2004248165A1 (en) * 2003-06-11 2004-12-23 Biogen Idec Ma Inc. Method to increase protein production in culture
SG153714A1 (en) 2003-08-06 2009-07-29 Senomyx Inc T1r hetero-oligomeric taste receptors, cell lines that express said receptors, and taste compounds
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US11311574B2 (en) 2003-08-08 2022-04-26 Sangamo Therapeutics, Inc. Methods and compositions for targeted cleavage and recombination
RU2006114432A (ru) * 2003-09-30 2007-11-20 Лексикон Дженетикс Инкорпорейтед (Us) Способы и композиции для определения функции гена
US20050148512A1 (en) * 2003-11-10 2005-07-07 Angiotech International Ag Medical implants and fibrosis-inducing agents
ES2610964T3 (es) 2003-11-20 2017-05-04 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Células madre multipotentes postnatales de ligamento periodontal humano y usos
US20080292581A1 (en) * 2003-12-03 2008-11-27 Delta Biotechnology Limited Interleukin-11 Fusion Proteins
PL1696947T3 (pl) * 2003-12-19 2014-08-29 Hoffmann La Roche Zastosowanie erytropoetyny w leczeniu zaburzeń dystrybucji żelaza w przewlekłych chorobach zapalnych jelit
AU2005206885B2 (en) * 2004-01-14 2012-02-02 Ohio University Methods of producing peptides/proteins in plants and peptides/proteins produced thereby
US7250298B2 (en) * 2004-04-07 2007-07-31 The University Of Chicago Monomeric red fluorescent proteins
US8623812B2 (en) 2004-04-19 2014-01-07 Ohio University Cross-linkable glycoproteins and methods of making the same
CA2567526A1 (en) * 2004-05-26 2005-12-15 Wisconsin Alumni Research Foundation Cancer treatment method by inhibiting mage gene expression or function
WO2006017673A2 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
US20060063231A1 (en) * 2004-09-16 2006-03-23 Sangamo Biosciences, Inc. Compositions and methods for protein production
JP2008529972A (ja) * 2004-12-22 2008-08-07 クロス・バイオサージェリー・アクチェンゲゼルシャフト 酵素的に分解可能な連結を通じて生物活性因子が組み入れられている合成バイオマテリアル
CN101133156A (zh) 2004-12-30 2008-02-27 科学、技术与研究机构 中国仓鼠凋亡相关基因
EP1833522B1 (en) * 2005-01-06 2016-06-22 Kuros Biosurgery AG Supplemented matrices for the repair of bone fractures
WO2006073711A2 (en) * 2005-01-06 2006-07-13 Kuros Biosurgery Ag Use of a matrix comprising a contrast agent in soft tissues
US8575101B2 (en) 2005-01-06 2013-11-05 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
US20090104159A1 (en) 2005-02-10 2009-04-23 Felipe Prosper Vascular/Lymphatic Endothelial Cells
US20060194740A1 (en) * 2005-02-25 2006-08-31 Ulevitch Richard J NOD1 as an anti-tumor agent
US20060234973A1 (en) * 2005-04-14 2006-10-19 Kevin Fitzgerald Transcription factor RNA interference reagents and methods of use thereof
PA8672101A1 (es) 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
US20070011752A1 (en) * 2005-05-06 2007-01-11 American Integrated Biologics, Inc. Production of human proteins in transgenic animal saliva
EP3214095B1 (en) 2005-05-12 2019-12-11 ZymoGenetics, Inc. Compositions and methods for modulating immune responses
CN101252951B (zh) 2005-06-30 2011-12-21 森托科尔公司 抗il-23抗体、组合物、方法和用途
EP1904652A2 (en) * 2005-07-08 2008-04-02 Brystol-Myers Squibb Company Single nucleotide polymorphisms associated with dose-dependent edema and methods of use thereof
US20080242834A1 (en) * 2005-07-08 2008-10-02 Ohio University Methods of Predicting Hyp-Glycosylation Sites For Proteins Expressed and Secreted in Plant Cells, and Related Methods and Products
US20070202512A1 (en) * 2005-08-19 2007-08-30 Bristol-Myers Squibb Company Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereof
JP2009507835A (ja) 2005-09-09 2009-02-26 ジョンズ ホプキンス ユニバーシティ 抗体、アゴニストおよびアンタゴニストを用いてニューリチン遺伝子をターゲティングすることによる調節性ｔ細胞およびｄｃの機能の操作
US20070072795A1 (en) * 2005-09-28 2007-03-29 Anton Haselbeck Treatment of neurodegenerative disorders
CA2626082C (en) 2005-10-13 2017-04-11 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
CA2952660C (en) 2005-10-20 2018-09-11 Senomyx, Inc. Chimeric human sweet-umami and umami-sweet taste receptors
WO2007060495A1 (en) * 2005-10-25 2007-05-31 Cellectis I-crei homing endonuclease variants having novel cleavage specificity and use thereof
WO2007053732A2 (en) 2005-11-01 2007-05-10 Mayo Foundation For Medical Education And Research Promoter polymorphisms of the blys gene and use in diagnostic methods
RU2008115455A (ru) 2005-11-03 2009-12-10 Рэдпойнт Био Корпорэйшн (Us) Высокопроизводительный скрининг-анализ ионного канала trpm5
LT2548577T (lt) 2005-12-29 2017-04-10 Janssen Biotech, Inc. Žmogaus anti-il-23 antikūnai, kompozicijos, būdai ir panaudojimai
DE102006004008A1 (de) 2006-01-27 2007-08-02 Hannelore Prof. Dr. Dr. Ehrenreich Verfahren zur Behandlung und/oder Prophylaxe von Multipler Sklerose, sowie Verwendung von Erythropoietin zur Herstellung eines Arzneimittels zur intermittierenden Behandlung und/oder intermittierenden Prophylaxe von Multipler Sklerose
PT1986612E (pt) 2006-02-07 2012-11-06 Shire Human Genetic Therapies Composição estável de glucocerebrosidase
WO2007100870A2 (en) 2006-02-28 2007-09-07 The Trustees Of Columbia University In The City Of New York Methods for compact aggregation of dermal cells
EP2650305B1 (en) 2006-03-24 2024-05-08 Bioverativ Therapeutics Inc. PC5 as a factor IX propeptide processing enzyme
KR101387563B1 (ko) 2006-04-21 2014-04-25 세노믹스, 인코포레이티드 고효능의 조미용 향료를 포함하는 식품 조성물 및 이의 제조 방법
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
WO2008013861A2 (en) 2006-07-27 2008-01-31 Redpoint Bio Corporation Screening assay for inhibitors of trpa1 activation by a lower alkyl phenol
PL2054074T3 (pl) * 2006-08-04 2015-03-31 Prolong Pharmaceuticals Llc Zmodyfikowana erytropoetyna
EP2054437A2 (en) * 2006-08-07 2009-05-06 Teva Biopharmaceuticals USA, Inc. Albumin-insulin fusion proteins
JP2008044926A (ja) * 2006-08-14 2008-02-28 Trustees Of Columbia Univ In The City Of New York Ｗｎｔ信号伝達に関係した分泌タンパク質
EP2120998B1 (en) 2006-11-28 2013-08-07 HanAll Biopharma Co., Ltd. Modified erythropoietin polypeptides and uses thereof for treatment
WO2008116111A2 (en) * 2007-03-20 2008-09-25 Harold Brem Growth factor mediated cosmeceuticals and use thereof to enhance skin quality
WO2008116116A2 (en) * 2007-03-20 2008-09-25 Harold Brem Gm-csf cosmeceutical compositions and methods of use thereof
PL2136850T3 (pl) 2007-04-13 2012-07-31 Kuros Biosurgery Ag Polimeryczny uszczelniacz tkankowy
CN101681396A (zh) 2007-04-16 2010-03-24 动量制药公司 限定的糖蛋白产品以及相关方法
CL2008002054A1 (es) * 2007-07-17 2009-05-29 Hoffmann La Roche Metodo para la regeneracion de una columna de cromatografia de intercambio cationico despues de la elusion de eritropoyetina monopeguilada y metodo para obtener una eritropoyetina monopeguilada, incorporando el metodo de regeneracion de la columna de intercambio cationico.
AR067537A1 (es) * 2007-07-17 2009-10-14 Hoffmann La Roche Purificacion de polipeptidos pegilados
WO2009010107A1 (en) 2007-07-19 2009-01-22 Hannelore Ehrenreich Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis
WO2009015063A2 (en) 2007-07-23 2009-01-29 Centocor Methods and compositions for treating fibrosis related disorders using il-17 antagonists
HUE025137T2 (hu) 2007-08-21 2016-01-28 Senomyx Inc Készítményekben keserû ízt gátló (blokkoló) vegyületek
WO2009059305A2 (en) * 2007-11-01 2009-05-07 The University Of Chicago Red fluorescent proteins with enhanced bacterial expression, increased brightness and reduced aggregation
WO2009073511A2 (en) * 2007-11-30 2009-06-11 Mayo Foundation For Medical Education And Research Polymorphisms of the blys gene and use in diagnostic methods
JP2012512812A (ja) * 2007-12-28 2012-06-07 クロス・バイオサージェリー・アクチェンゲゼルシャフト フィブリンフォームに組込まれたｐｄｇｆ融合タンパク質
WO2009089380A2 (en) * 2008-01-08 2009-07-16 The Trustees Of Columbia University In The City Of New York Methods for p2ry5 mediated regulation of hair growth and mutants thereof
US20110104133A1 (en) 2008-05-06 2011-05-05 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
US8563697B2 (en) 2008-08-14 2013-10-22 Cephalon Australia Pty. Ltd. Anti-IL-12/IL-23 antibodies
DK2356269T3 (en) 2008-10-31 2016-08-15 Janssen Biotech Inc FIBRONECTIN TYPE III DOMAIN-BASED SCAFFOLD COMPOSITIONS, PROCEDURES AND APPLICATIONS
WO2010093627A2 (en) 2009-02-12 2010-08-19 Centocor Ortho Biotech Inc. Fibronectin type iii domain based scaffold compositions, methods and uses
US20120191032A1 (en) 2009-07-15 2012-07-26 Newsouth Innovations Pty. Limited Method of providing agents to the cochlea
MX344786B (es) 2009-07-28 2017-01-06 Shire Human Genetic Therapies Composiciones y metodos para tratar enfermedad de gaucher.
PL3482767T3 (pl) 2009-08-28 2022-02-14 Icahn School Of Medicine At Mount Sinai Enzymatyczna terapia zastępcza ze zwiększaniem dawki do leczenia niedoboru kwaśnej sfingomielinazy
EP2525808A2 (en) 2010-01-19 2012-11-28 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for male reproductive disorders
NO2552961T3 (hu) 2010-03-30 2018-05-19
ES2500048T3 (es) 2010-09-14 2014-09-29 F. Hoffmann-La Roche Ag Procedimiento para purificar eritropoyetina pegilada
PT2635299T (pt) 2010-11-02 2019-10-14 Univ Columbia Métodos de tratamento de distúrbios de perda de cabelo
CN105420267A (zh) 2010-11-30 2016-03-23 诺维信股份有限公司 用于在真菌细胞中表达基因的启动子
US9862928B2 (en) 2010-12-03 2018-01-09 Regents Of The University Of Minnesota Generation of natural killer cells and lymphoid tissue inducer-like (LTi-like) NK-22 cells
EP2649419B1 (en) 2010-12-07 2020-05-20 Vnomics Corp. System for measuring and reducing vehicle fuel waste
DK2652138T3 (en) 2010-12-16 2018-01-22 Novozymes Inc Promoters for expression of genes in a fungal cell
AU2011352205B2 (en) 2010-12-31 2016-06-16 Bioatla, Llc Express humanization of antibodies
WO2012101671A1 (en) 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
CA2828811C (en) 2011-03-03 2021-09-21 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
WO2012123028A1 (en) 2011-03-16 2012-09-20 Kuros Biosurgery Ag Pharmaceutical formulation for use in spinal fusion
RU2495933C2 (ru) * 2011-05-30 2013-10-20 Общество с ограниченной ответственностью "Лаборатория медицинской биотехнологии" (ООО "ЛМБТ") ПЛАЗМИДА ДЛЯ ЭКСПРЕССИИ В КЛЕТКАХ БАКТЕРИИ РОДА Escherichia ПРЕДШЕСТВЕННИКА РЕКОМБИНАНТНОГО ФРАГМЕНТА ТКАНЕВОГО АКТИВАТОРА ПЛАЗМИНОГЕНА (ТАП) ЧЕЛОВЕКА (РЕТЕПЛАЗЫ), БАКТЕРИЯ, ПРИНАДЛЕЖАЩАЯ К РОДУ Escherichia, - ПРОДУЦЕНТ ПРЕДШЕСТВЕННИКА РЕКОМБИНАНТНОГО ФРАГМЕНТА ТАП ЧЕЛОВЕКА (РЕТЕПЛАЗЫ) ИЛИ [-1]МЕТИОНИЛ-ФРАГМЕНТ ТАП ЧЕЛОВЕКА (РЕТЕПЛАЗЫ), ПРЕДШЕСТВЕННИК РЕКОМБИНАНТНОГО ФРАГМЕНТА ТАП ЧЕЛОВЕКА (РЕТЕПЛАЗЫ), СПОСОБ ПОЛУЧЕНИЯ ПРЕДШЕСТВЕННИКА РЕКОМБИНАНТНОГО ФРАГМЕНТА ТАП ЧЕЛОВЕКА (РЕТЕПЛАЗЫ)
WO2013013017A2 (en) * 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics
KR102096752B1 (ko) 2012-03-02 2020-04-02 샤이어 휴먼 지네틱 테라피즈 인크. Ｉｉｉ형 고셔병을 치료하기 위한 조성물 및 방법
US20130318645A1 (en) * 2012-05-22 2013-11-28 Georgia Regent University Methods and Vectors for Gene Targeting With Inducible Specific Expression
CA2878640C (en) 2012-07-13 2023-10-24 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
WO2014016873A1 (en) 2012-07-26 2014-01-30 Jcr Pharmaceuticals Co., Ltd. Method for production of recombinant human alpha-galactosidase a
CN103864913A (zh) 2012-12-18 2014-06-18 联亚生技开发股份有限公司 重组蛋白
EP2851086A1 (en) 2013-09-20 2015-03-25 Sanofi Serpins: methods of therapeutic ß-cell regeneration and function
US20160002316A1 (en) 2013-02-22 2016-01-07 Joslin Diabetes Center Serpins: methods of therapeutic beta-cell regeneration and function
EP2769732A1 (en) 2013-02-22 2014-08-27 Sanofi Serpins: methods of therapeutic beta-cell regeneration and function
US10066001B2 (en) 2013-03-15 2018-09-04 Apotex Inc. Enhanced liquid formulation stability of erythropoietin alpha through purification processing
US10052364B2 (en) 2013-03-15 2018-08-21 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for cognitive disorders
US10239951B2 (en) 2013-05-08 2019-03-26 Zymeworks Inc. Bispecific HER2 and HER3 antigen binding constructs
WO2014201511A1 (en) 2013-06-21 2014-12-24 Gary David Housley Method and apparatus for close-field electroporation
US11306328B2 (en) * 2013-07-26 2022-04-19 President And Fellows Of Harvard College Genome engineering
EP3226889A4 (en) 2014-11-19 2018-11-21 The Trustees of Columbia University in the City of New York Osteocalcin as a treatment for frailty associated with aging
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
WO2016116966A1 (en) 2015-01-22 2016-07-28 Jcr Pharmaceuticals Co., Ltd. Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins
EP3702470A3 (en) 2015-09-09 2020-10-07 The Trustees of Columbia University in the City of New York Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
CN108290948B (zh) 2015-09-21 2021-10-29 伊拉兹马斯大学医疗中心 抗-cd47抗体及使用方法
US10188750B1 (en) 2015-10-23 2019-01-29 University Of South Florida Self-replicating cell selective gene delivery compositions, methods, and uses thereof
EP3370733B1 (en) 2015-11-02 2021-07-14 Board of Regents, The University of Texas System Methods of cd40 activation and immune checkpoint blockade
CA3019164A1 (en) 2016-03-29 2017-10-05 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-il12/23 antibody
MX2019000641A (es) 2016-07-15 2019-06-10 Poseida Therapeutics Inc Composiciones de mucina1-receptor de antigeno quimerico y metodos para su uso.
WO2018011381A1 (en) 2016-07-15 2018-01-18 F. Hoffmann-La Roche Ag Method for purifying pegylated erythropoietin
JP2019524721A (ja) 2016-07-15 2019-09-05 ポセイダ セラピューティクス， インコーポレイテッド キメラ抗原受容体および使用方法
JP2020500152A (ja) 2016-09-30 2020-01-09 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で乾癬を治療する安全かつ有効な方法
US20190119636A1 (en) 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
JP2019528760A (ja) 2016-09-30 2019-10-17 ポセイダ セラピューティクス， インコーポレイテッド 改変された幹細胞メモリーｔ細胞、その作製方法およびその使用方法
BR112019006865A2 (pt) 2016-10-06 2019-06-25 Poseida Therapeutics Inc caspases induzíveis e métodos para uso
AU2017362222A1 (en) 2016-11-16 2019-05-30 Janssen Biotech, Inc. Method of treating psoriasis with anti-IL-23 specific antibody
AU2017396503A1 (en) 2017-01-30 2019-07-11 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, and methods for the treatment of active Psoriatic arthritis
WO2018147915A1 (en) 2017-02-07 2018-08-16 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
AU2018235756B2 (en) 2017-03-13 2024-08-08 Poseida Therapeutics, Inc. Compositions and methods for selective elimination and replacement of hematopoietic stem cells
AU2018329741A1 (en) 2017-09-08 2020-03-19 Poseida Therapeutics, Inc. Compositions and methods for chimeric ligand receptor (CLR)-mediated conditional gene expression
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
US10329543B2 (en) 2017-10-23 2019-06-25 Poseida Therapeutics, Inc. Modified stem cell memory T cells, methods of making and methods of using same
JP7391845B2 (ja) 2017-12-01 2023-12-05 シージェン インコーポレイテッド Ｃｄ４７抗体及びがんを治療するためのその使用
US20210139557A1 (en) 2017-12-20 2021-05-13 Poseida Therapeutics, Inc. Vcar compositions and methods for use
EP3731873B1 (en) 2017-12-29 2022-01-26 F. Hoffmann-La Roche AG Process for providing pegylated protein composition
CN111741770A (zh) 2017-12-29 2020-10-02 豪夫迈·罗氏有限公司 用于提供聚乙二醇化蛋白质组合物的方法
ES2905105T3 (es) 2017-12-29 2022-04-07 Hoffmann La Roche Procedimiento para proporcionar una composición de proteína PEGilada
AU2019232624A1 (en) 2018-03-05 2020-09-10 Janssen Biotech, Inc. Methods of treating Crohn's disease with anti-IL23 specific antibody
AU2019230192A1 (en) 2018-03-07 2020-10-08 Poseida Therapeutics, Inc. CARTyrin compositions and methods for use
EP3781942B1 (en) 2018-04-20 2022-06-01 Janssen Biotech, Inc. Transition analysis method for chromatography column qualification
EP3824295A4 (en) 2018-07-18 2022-04-27 Janssen Biotech, Inc. PREDICTORS OF PROLONGED RESPONSE AFTER TREATMENT WITH AN ANTI-IL23 SPECIFIC ANTIBODY
WO2020051374A1 (en) 2018-09-05 2020-03-12 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use
MD3883606T3 (ro) 2018-09-24 2024-03-31 Janssen Biotech Inc Metodă sigură și eficientă de tratament al colitei ulcerative cu anticorpi anti-IL12/IL23
KR20210093973A (ko) 2018-11-20 2021-07-28 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 건선을 치료하는 안전하고 효과적인 방법
JP2022514561A (ja) 2018-12-18 2022-02-14 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ１２／ｉｌ２３抗体でループスを治療する安全かつ有効な方法
JP2022513507A (ja) 2018-12-20 2022-02-08 ポセイダ セラピューティクス，インコーポレイティド ナノトランスポゾン組成物および使用方法
BR112021013903A2 (pt) 2019-01-15 2021-09-21 Janssen Biotech, Inc. Composições e métodos de anticorpos anti-tnf para o tratamento da artrite idiopática juvenil
CA3127748A1 (en) 2019-01-23 2020-07-30 Janssen Biotech, Inc. Anti-tnf antibody compositions for use in methods for the treatment of psoriatic arthritis
EP3938390A1 (en) 2019-03-14 2022-01-19 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
US20200291107A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Manufacturing Methods for Producing Anti-IL12/IL23 Antibody Compositions
EA202192508A1 (ru) 2019-03-14 2022-03-29 Янссен Байотек, Инк. Способы получения композиций антитела к фно
EP3938391A1 (en) 2019-03-14 2022-01-19 Janssen Biotech, Inc. Methods for producing anti-tnf antibody compositions
US20200331996A1 (en) 2019-03-18 2020-10-22 Janssen Biotech, Inc. Method of Treating Psoriasis in Pediatric Subjects with Anti-IL12/IL23 Antibody
KR20220012883A (ko) 2019-05-23 2022-02-04 얀센 바이오테크 인코포레이티드 Il-23 및 tnf 알파에 대한 항체의 병용요법으로 염증성 장질환을 치료하는 방법
EP3976648A1 (en) 2019-06-03 2022-04-06 Janssen Biotech, Inc. Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis
CN114173873A (zh) 2019-06-03 2022-03-11 詹森生物科技公司 用于治疗活动性强直性脊柱炎的抗tnf抗体、组合物和方法
US20220306727A1 (en) 2019-06-05 2022-09-29 Seagen Inc. Methods of Purifying Masked Antibodies
TW202112354A (zh) 2019-06-05 2021-04-01 美商西雅圖遺傳學公司 遮蔽抗體調配物
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
WO2021038296A2 (en) 2019-08-27 2021-03-04 Tonix Pharma Holdings Limited Modified tff2 polypeptides
US20220372105A1 (en) 2019-09-05 2022-11-24 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use
CN115135672A (zh) 2019-12-20 2022-09-30 波赛达治疗公司 抗muc1组合物和使用方法
AU2021230361A1 (en) 2020-03-04 2022-09-08 Poseida Therapeutics, Inc. Compositions and methods for the treatment of Metabolic Liver Disorders
US20230121433A1 (en) 2020-03-11 2023-04-20 Poseida Therapeutics, Inc. Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
CA3174777A1 (en) 2020-04-14 2021-10-21 Eric M. Ostertag Compositions and methods for use in the treatment of cancer
US20240000969A1 (en) 2020-10-21 2024-01-04 Poseida Therapeutics San Diego Compositions and methods for delivery of nucleic acids
WO2022159414A1 (en) 2021-01-22 2022-07-28 University Of Rochester Erythropoietin for gastroinfestinal dysfunction
WO2022182797A1 (en) 2021-02-23 2022-09-01 Poseida Therapeutics, Inc. Genetically modified induced pluripotent stem cells and methods of use thereof
WO2022182792A1 (en) 2021-02-23 2022-09-01 Poseida Therapeutics, Inc. Compositions and methods for delivery of nucleic acids
WO2022187671A1 (en) 2021-03-04 2022-09-09 Poseida Therapeutics, Inc. Compositions and methods for the treatment of hemophilia
AU2022233792A1 (en) 2021-03-12 2023-10-26 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
MX2023010697A (es) 2021-03-12 2023-11-23 Janssen Biotech Inc Método para tratar pacientes con artritis psoriásica con respuesta inadecuada a la terapia de tnf con anticuerpo específico anti-il23.
JP2024527586A (ja) 2021-07-09 2024-07-25 ヤンセン バイオテツク，インコーポレーテツド 抗－ｔｎｆ抗体組成物を産生するための製造方法
CN117916260A (zh) 2021-07-09 2024-04-19 詹森生物科技公司 用于制备抗il12/il23抗体组合物的制造方法
JP2024526315A (ja) 2021-07-09 2024-07-17 ヤンセン バイオテツク，インコーポレーテツド 抗ｔｎｆ抗体組成物を製造するための製造方法
WO2023288236A1 (en) 2021-07-14 2023-01-19 Seagen Inc. Antibody masking domains
WO2023049825A1 (en) 2021-09-24 2023-03-30 Seagen Inc. Improved antibody masking domains
KR20240099249A (ko) 2021-10-04 2024-06-28 포세이다 테라퓨틱스, 인크. 트랜스포사제 및 이의 용도
CA3233506A1 (en) 2021-10-04 2023-04-13 Joseph S. LUCAS Transposon compositions and methods of use thereof
AU2022374890A1 (en) 2021-10-29 2024-06-13 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
US20230151087A1 (en) 2021-11-15 2023-05-18 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
US20230159633A1 (en) 2021-11-23 2023-05-25 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
AU2023210287A1 (en) 2022-01-21 2024-09-05 Poseida Therapeutics, Inc. Compositions and methods for delivery of nucleic acids
WO2023164573A1 (en) 2022-02-23 2023-08-31 Poseida Therapeutics, Inc. Genetically modified cells and methods of use thereof
US20230374122A1 (en) 2022-05-18 2023-11-23 Janssen Biotech, Inc. Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody
WO2024036273A1 (en) 2022-08-11 2024-02-15 Poseida Therapeutics, Inc. Chimeric cd8-alpha co-receptor compositions and methods of use
WO2024091824A1 (en) 2022-10-26 2024-05-02 Ada Forsyth Institute, Inc. Differentiation and reprogramming of chondrocyte
WO2024110898A1 (en) 2022-11-22 2024-05-30 Janssen Biotech, Inc. Method of treating ulcerative colitis with anti-il23 specific antibody
WO2024129459A1 (en) 2022-12-16 2024-06-20 University Of Rochester Repairmen! of barrier dysfunction in esophagus
WO2024178086A1 (en) 2023-02-21 2024-08-29 Poseida Therapeutics, Inc. Aav piggybac transposon polynucleotide compositions and methods of use therefor
WO2024178069A1 (en) 2023-02-21 2024-08-29 Poseida Therapeutics, Inc. Compositions and methods for genome editing
WO2024178055A1 (en) 2023-02-21 2024-08-29 Poseida Therapeutics, Inc. Compositions and methods for genome editing
WO2024211512A2 (en) 2023-04-05 2024-10-10 Poseida Therapeutics, Inc. Transposases and uses thereof
WO2024211509A1 (en) 2023-04-05 2024-10-10 Poseida Therapeutics, Inc. Transposase polynucleotides and uses thereof
WO2024211505A1 (en) 2023-04-05 2024-10-10 Poseida Therapeutics, Inc. Chimeric transposases and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656134A (en) * 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
AU572108B2 (en) * 1983-01-19 1988-05-05 Genentech Inc. Human tpa production using vectors coding for dhfr protein
US4680174A (en) * 1984-05-24 1987-07-14 Damon Biotech, Inc. Induction of immune response by immunization with encapsulated antigen-producing cells
US4822736A (en) * 1984-07-05 1989-04-18 Baylor College Of Medicine Amplification of adenosine deaminase genes in mammalian cells using adenosine, alanosine, uridine, and deoxycoformycin
DE3681787D1 (de) * 1985-07-05 1991-11-07 Whitehead Biomedical Inst Expression von fremdem genetischem material in epithelzellen.
DE3789678T2 (de) * 1986-02-27 1994-08-11 Snow Brand Milk Prod Co Ltd Herstellung von erythropoietinproduzierenden Zellen und Verfahren zur Herstellung von Erythropoietin mit Verwendung dieser Zellen.
DK173067B1 (da) * 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
GB8615942D0 (en) * 1986-06-30 1986-08-06 Animal & Food Research Council Peptide production
PT87363B (pt) * 1987-05-01 1993-11-30 Gen Hospital Corp Metodo para alterar a concentracao de um produto genetico
GB8718779D0 (en) * 1987-08-07 1987-09-16 Grosveld F G Dna sequence & expression vector
FR2646438B1 (fr) * 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US5043270A (en) * 1989-03-31 1991-08-27 The Board Of Trustees Of The Leland Stanford Junior University Intronic overexpression vectors
DK0478696T3 (da) * 1989-06-23 1995-06-26 Us Health Effektiv fremgangsmåde til identificerbar udtrykkelse af ikke-selekterbare gener
ATE174058T1 (de) * 1989-11-06 1998-12-15 Cell Genesys Inc Herstellung von proteinen mittels homologer rekombination
US5272071A (en) * 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
RU2128227C1 (ru) * 1989-12-22 1999-03-27 Апплайд Резеч Системз АРС Холдинг Н.В. (NL) (Антильские острова) Способ активации транскрипционно-молчащего гена
WO1991013151A1 (en) * 1990-02-22 1991-09-05 Biogen, Inc. Improved expression of polypeptides
IT1241123B (it) * 1990-04-19 1993-12-29 Consiglio Nazionale Ricerche Cellule umane per l'elevata espressione di geni inseriti in dna ricombinanti episomiali,loro preparazione e loro impiego
CA2084774A1 (en) * 1990-06-12 1991-12-13 Allan Bradley Method for homologous recombination in animal and plant cells
US5612205A (en) * 1990-08-29 1997-03-18 Genpharm International, Incorporated Homologous recombination in mammalian cells
JP3150340B2 (ja) * 1990-11-13 2001-03-26 イムネクス コーポレイション 二機能選択可能融合遺伝子
ATE177784T1 (de) * 1990-12-07 1999-04-15 Univ Florida Rekombinante zellen, die stark chromosomal- integrierte heterologe gene exprimieren
SG93780A1 (en) * 1991-05-06 2003-01-21 Cell Genesys Inc Gene manipulation and expression using genomic elements
CA2092695A1 (en) * 1991-05-15 1992-11-16 Oliver Smithies Genomic modifications with homologous dna targeting
AU2515992A (en) * 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
NZ245015A (en) * 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
MX9305183A (es) * 1992-08-27 1994-05-31 Us Agriculture Intron portatil, molecula de adn genomico viral, virus vivo y vacuna que los contiene y metodo para su obtencion.
TW402639B (en) * 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery

Also Published As

Publication number Publication date
WO1995031560A1 (en) 1995-11-23
RU2267533C2 (ru) 2006-01-10
HU9603144D0 (en) 1997-01-28
SK146196A3 (en) 1998-02-04
NO964802L (no) 1997-01-09
CZ295115B6 (cs) 2005-05-18
HUT76844A (en) 1997-11-28
NZ285945A (en) 1998-03-25
AU709058B2 (en) 1999-08-19
US5641670A (en) 1997-06-24
FI964536A (fi) 1997-01-09
AU2550495A (en) 1995-12-05
CZ325896A3 (en) 1997-12-17
EP0759082A1 (en) 1997-02-26
MX9605542A (es) 1998-05-31
BR9507874A (pt) 1997-08-19
UA34493C2 (uk) 2001-03-15
KR970703429A (ko) 1997-07-03
IL113708A0 (en) 1995-08-31
CA2190289A1 (en) 1995-11-23
JPH10500570A (ja) 1998-01-20
KR100379356B1 (ko) 2003-06-09
FI964536A0 (fi) 1996-11-12
NO964802D0 (no) 1996-11-12

Similar Documents

Publication Publication Date Title
IL113708A0 (en) Protein production and protein delivery
ZA962116B (en) Protein production and delivery
EP0960934A4 (en) PHYTASE AND METHOD FOR THE PRODUCTION THEREOF
IL115720A (en) Liquiflash particles and their production
GB9419021D0 (en) Therapeutic protein
GB9423372D0 (en) Proteins and their uses
HU9600395D0 (en) New protein and processes for its production
IL113725A0 (en) Preparing recombinant aprotini and its variants
HUP9801330A3 (en) Novel pka-binding proteins and uses thereof
IL115317A0 (en) Proteins
IL129909A0 (en) Novel calpaines their production and use thereof
EP0729975A4 (en) PROTEIN ECDN AND DNA ENCODING THIS PROTEIN
GB9519865D0 (en) Protein
GB9622436D0 (en) Protein
PL324340A1 (en) Novel quinoxalinophosphonic and quinoxalinoalkanophosphonic acids
GB2292978B (en) Delivery valves
IL115853A0 (en) Aryloxycycloalkenyl and aryloxyiminocyclo-alkenylhydroxyureas
EP0857732A4 (en) HUMAN PROTEIN ANALOGUE TO PEC-60 AND THE DNA THAT ENCODES IT
GB2294451B (en) Container and its manufacture
LTIP2063A (en) Dessert-cheese and manufacture thereof
GB9420989D0 (en) Protein
GB9422293D0 (en) Therapeutic protein
GB9419804D0 (en) Proteins
GB9411089D0 (en) Proteins
GB9424025D0 (en) Proteins